RFK Jr. May Want To Ban Prescription Drug Ads, But Can He? [Forbes]
Amgen Inc. (AMGN)
Last amgen inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.amgen.com
Company Research
Source: Forbes
Trump speak during an event in the East Room of the White House in Washington, March 12, 2025. (AP Photo/Alex Brandon, File) Copyright 2025 The Associated Press. All rights reserved It's been rumored for quite some time that the Secretary of Health and Human Services Robert F. Kennedy Jr. may pursue banning prescription drug advertisements on television. But can he? Probably not. During President Trump's first term in office, his administration tried to require disclosure of list prices in pharmaceutical commercials. This was then shot down by a federal court judge. Attempts now at a (partial) ban are unlikely to come to fruition. Nonetheless, raising the issue has sparked a discussion around the pros and cons of direct-to-consumer drug
Read more
Impact Snapshot
Event Time:
AMGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AMGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AMGN alerts
High impacting Amgen Inc. news events
Weekly update
A roundup of the hottest topics
AMGN
News
- Amgen Inc. (NASDAQ: AMGN) had its price target raised by analysts at UBS Group AG from $315.00 to $319.00. They now have a "neutral" rating on the stock.MarketBeat
- [Corrected] Sandoz files antitrust litigation against Amgen regarding patient access to etanercept biosimilar in the US [Yahoo! Finance]Corrected
- Sandoz challenges Amgen's Enbrel patents in US antitrust lawsuit [Yahoo! Finance]Yahoo! Finance
- IMDELLTRA® DEMONSTRATED SUPERIOR OVERALL SURVIVAL IN SMALL CELL LUNG CANCER [Yahoo! Finance]Yahoo! Finance
- IMDELLTRA® DEMONSTRATED SUPERIOR OVERALL SURVIVAL IN SMALL CELL LUNG CANCERPR Newswire
AMGN
Earnings
- 2/4/25 - Beat
AMGN
Sec Filings
- 4/9/25 - Form DEFA14A
- 4/9/25 - Form DEF
- 4/2/25 - Form ARS
- AMGN's page on the SEC website